Citigroup Maintains Neutral on Zimmer Biomet Holdings, Lowers Price Target to $95

Benzinga Newsdesk www.benzinga.com Negative 59.4%

Neg 59.4% Neu 0% Pos 0%

Citigroup analyst Joanne Wuensch maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Neutral and lowers the price target from $98 to $95.